Lymphoma and myeloma patients and caregivers are invited to meet with cancer experts and learn of the latest developments in disease treatment and care at the “Lymphoma/Myeloma Update for Patients: What’s New for 2016” symposium set for Jan. 9, 2016, in Houston, Texas.
The event, at the Omni Houston Westside, is hosted by the University of Texas MD Anderson Cancer Center. Multiple Myeloma Opportunities for Research & Education (MORE), the Leukemia & Lymphoma Society, and Patient Power are among its main sponsors.
“This is a tremendous opportunity for patients and their caregivers and families to hear from some of the top experts in all areas of treatment for lymphoma and myeloma,” Jatin Shah, M.D. and Associate Professor at the Department of Lymphoma/Myeloma, said in a news release. “This event is designed to answer patients’ questions about the newest research and therapies for these diseases.”
Other symposium goals are to inform the community about the latest research and upcoming clinical trials, and increasing awareness strategies for dealing with lymphoma or myeloma. The event intends to build a bridge of knowledge, communication and cooperation among researchers, healthcare professionals, patients, and caregivers.
Presentation topics include:
- Transplant therapy
- New treatment options for recently diagnosed and relapsed lymphoma/myeloma, and new clinical trials opportunities
- Latest advances for therapies such as CAR T cells, other immunotherapies, stem cell transplantation, and strategies for coping with chronic disease
The event starts at 7 a.m. with a registration period and breakfast, and the first session begins at 8 a.m. The morning session will be dedicated to myeloma, and the afternoon session addresses lymphoma. More information on the planned presentations can found on the symposium agenda here. Registration, which costs $20, can be completed online here.
Alternatively, more information can be had by calling 713-745-6130; those with special dietary or ADA accommodation needs can call 866-849-5866.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?